ClinicalTrials.gg
RecruitingNCT04490317Updated Nov 10, 2026

CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)

An observational study in Carbon Monoxide Poisoning, Myocardial Injury and Neurologic Deficits, sponsored by Wonju Severance Christian Hospital. Recruiting at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Wonju Severance Christian Hospital · Observational

How we know

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 3 months later.
Updated Nov 10, 2026First site in South KoreaNo longer in Korea, Republic of+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Sex
All
01

Study summary

This prospective cohort study enrolls subjects who experience carbon monoxide (CO) poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments and short and long-term outcomes in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through various ways and the association between complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.

Read the detailed description

This prospective cohort study enrolls subjects who experience CO poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments, including hyperbaric oxygen therapy (HBO), therapeutic hypothermia (TH), and additional drugs, and short and long-term outcomes, such as neurocognitive sequelae or mortality, in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through a variety of ways, such as magnetic resonance image (MRI), computed tomography (CT), ultrasound, and laboratory test, and the association between various complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.

02

Conditions studied

  • Carbon Monoxide Poisoning
  • Myocardial Injury
  • Neurologic Deficits
  • Image, Body
  • Therapy
  • Prognostic Factors
  • Complications
03

In context

Carbon Monoxide Poisoning

44 studies on the registry are indexed under Carbon Monoxide Poisoning; 8 are open to participants now.

This study's planned enrollment of 1,500 is above the median of 104 across 25 observational studies indexed under Carbon Monoxide Poisoning.

Browse Carbon Monoxide Poisoning studies →

Lead sponsor

Wonju Severance Christian Hospital is the lead sponsor of 43 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Acute CO poisoning

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute CO poisoning

Exclusion criteria

Exclusion Criteria:

  • Declined to enrollment in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute CO poisoning

    A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).

    Diagnostic Test: Cardiac MRI · Procedure: Hyperbaric oxygen therapy

Interventions

  • Diagnostic testCardiac MRI

    1. Cardiac MRI be taken to CO poisoned patients 2. Cardiac CT be taken to CO poisoned patients 3. TTE be taken to CO poisoned patients 4. Brain MRI be taken to CO poisoned patients 5. Neurocognitive function tests be taken to CO poisoned patients 6. Laboratory tests be taken to CO poisoned patients

    Also known as: Cardiac CT, Transthoracic echocardiography (TTE), Brain MRI, Neurocognitive function tests, Laboratory tests

  • ProcedureHyperbaric oxygen therapy

    1. Hyperbaric oxygen therapy be used for CO poisoned patients 2. Therapeutic hypothermia be used for CO poisoned patients

    Also known as: Therapeutic hypothermia

06

What researchers measure

Primary outcomes

  1. Therapeutic response to HBO at 1 month

    Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 1 month after CO exposure

    Time frame: At 1 month after CO exposure

  2. Therapeutic response to HBO at 6 months

    Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 6 months after CO exposure

    Time frame: At 6 months after CO exposure

  3. Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as neurocognitive function tests

    Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month

    Time frame: Within 1 month after CO exposure

  4. Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as neurocognitive function tests

    Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month

    Time frame: Within 1 month after CO exposure

  5. Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as neurocognitive function tests

    Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month

    Time frame: Within 1 month after CO exposure

Secondary outcomes

  1. Therapeutic response to HBO at 12 months

    Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 12 months after CO exposure

    Time frame: At 12 months after CO exposure

  2. Therapeutic response to TH combined with HBO at 1 month

    Therapeutic response to TH combined with HBO in acute severe CO poisoning at 1 month after CO exposure

    Time frame: At 1 month after CO exposure

  3. Therapeutic response to TH combined with HBO at 6 months

    Therapeutic response to TH combined with HBO in acute severe CO poisoning at 6 months after CO exposure

    Time frame: At 6 months after CO exposure

  4. Therapeutic response to TH combined with HBO at 12 months

    Therapeutic response to TH combined with HBO in acute severe CO poisoning at 12 months after CO exposure

    Time frame: At 12 months after CO exposure

  5. Therapeutic response to HBO according to presence of apolipoprotein E4 at 1 month

    Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 1 month after CO exposure

    Time frame: At 1 month after CO exposure

  6. Therapeutic response to HBO according to presence of apolipoprotein E4 at 6 months

    Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 6 months after CO exposure

    Time frame: At 6 months after CO exposure

  7. Therapeutic response to HBO according to presence of apolipoprotein E4 at 12 months after CO exposure

    Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 12 months after CO exposure

    Time frame: At 12 months after CO exposure

  8. Cardiac injury evaluated by cardiac MRI in acute phase

    Cardiac injury related to CO poisoning evaluated by cardiac MRI in acute phase

    Time frame: Within 1 month after CO exposure

  9. Cardiac injury evaluated by cardiac MRI in chronic phase

    Cardiac injury related to CO poisoning evaluated by cardiac MRI in chronic phase

    Time frame: Follow-up cardiac MRI (at 4-8 months after CO exposure)

  10. Cardiac injury evaluated by cardiac CT

    Cardiac injury evaluated by cardiac CT in CO poisoning

    Time frame: Within 1 month after CO exposure

  11. Cardiac injury evaluated by TTE in acute phase

    Cardiac injury related to CO poisoning evaluated by TTE in acute phase

    Time frame: Within 14 days after CO exposure

  12. Cardiac injury evaluated by TTE in chronic phase

    Cardiac injury related to CO poisoning evaluated by TTE in chronic phase

    Time frame: Within 4-8 months after CO exposure

  13. Brain injury evaluated by brain imaging modality related to CO poisoning

    Brain injury evaluated by brain MRI in CO poisoning

    Time frame: Within 6 months after CO exposure

  14. Brain injury related to CO poisoning

    Brain injury evaluated by laboratory tests in CO poisoning

    Time frame: Within 6 months after CO exposure

  15. Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure

    Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure

    Time frame: Outcomes at 1 month after CO exposure

  16. Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure

    Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure

    Time frame: Outcomes at 6 months after CO exposure

  17. Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure

    Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure

    Time frame: Outcomes at 12 months after CO exposure

  18. Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure

    Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure

    Time frame: Outcomes at 5 years after CO exposure

  19. Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 1 month after CO exposure

  20. Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 6 months after CO exposure

  21. Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 12 months after CO exposure

  22. Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 5 years after CO exposure

  23. Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 1 month after CO exposure

  24. Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 6 months after CO exposure

  25. Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 12 months after CO exposure

  26. Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests

    Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc

    Time frame: Outcomes at 5 years after CO exposure

  27. Therapeutic response to drugs at 1 month

    Therapeutic response to additional drug including steroid at 1 month after CO exposure

    Time frame: At 1 month after CO exposure

  28. Therapeutic response to drugs at 6 months

    Therapeutic response to additional drug including steroid at 6 months after CO exposure

    Time frame: At 6 months after CO exposure

  29. Therapeutic response to drugs at 12 months

    Therapeutic response to additional drug including steroid at 12 months after CO exposure

    Time frame: At 12 months after CO exposure

  30. Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 1 month

    Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 1 month after CO exposure

    Time frame: At 1 month after CO exposure

  31. Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 6 months

    Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 6 months after CO exposure

    Time frame: At 6 months after CO exposure

  32. Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 12 months

    Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 12 months after CO exposure

    Time frame: At 12 months after CO exposure

  33. Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 5 years

    Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 5 years after CO exposure

    Time frame: At 5 years after CO exposure

  34. Organ injury related to CO poisoning

    Organ injury, such as lung, kidney, liver, pancreas, or bowel, etc, related to CO poisoning

    Time frame: Within 6 months after CO exposure

  35. Complications related to CO poisoning

    Complications, such as pulmonary thromboembolism or rhabdomyolysis, etc, related to CO poisoning

    Time frame: Within 6 months after CO exposure

  36. Effect of HBO for delayed neurocognitive and psychological dysfunction at 1 year after onset

    Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 1 year after sequelae onset

    Time frame: Within 1 year after delayed neurocognitive and psychological sequelae onset

  37. Effect of HBO for delayed neurocognitive and psychological dysfunction at 2 years after onset

    Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 2 years after sequelae onset

    Time frame: Within 2 years after delayed neurocognitive and psychological sequelae onset

  38. Validation of methods evaluating neurocognitive and psychological outcomes

    Validation of methods evaluating neurocognitive and psychological outcomes within 6 months

    Time frame: Within 6 months after CO exposure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ahn GJ, Lee S, Heo YW, Cha YS. Mortality Risks and Causes in Previous Carbon Monoxide Poisoning: A Nationwide Population-Based Cohort Study. Crit Care Med. 2024 Dec 1;52(12):1866-1876. doi: 10.1097/CCM.0000000000006414. Epub 2024 Sep 18. PubMed 39298511 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2020 (actual). Primary completion is estimated for Dec 2030, 125 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2020
First posted
Jul 29, 2020
StartActual
Jul 29, 2020
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2035
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed — first site in South Korea; no longer in Korea, Republic of
Show site
  • Wonju Severance Christian Hospital · Wŏnju, South Korea
Show 1 removed
  • Wonju Severance Christian Hospital · Wonju, Korea, Republic of
Nov 10, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39298511 ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39298511 ↗
    1 site added, 1 site removed — first site in South Korea; no longer in Korea, Republic of
    Show site
    • Wonju Severance Christian Hospital · Wŏnju, South Korea
    Show 1 removed
    • Wonju Severance Christian Hospital · Wonju, Korea, Republic of
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04490317
Lead sponsor
Wonju Severance Christian Hospital
Responsible party
Yong Sung Cha (Assistant Professor, Wonju Severance Christian Hospital) — Principal investigator
First posted
Jul 29, 2020
Start date
Jul 29, 2020
Primary completion
Dec 2030 (estimated)
Completion
Dec 2035 (estimated)
Last update
Nov 10, 2026

Study contacts

Yong Sung Cha, MD
Contact
emyscha@yonsei.ac.kr
+82-33-741-1615
Yong Sung Cha, MD
principal investigator · Wonju Severance Christian Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion